⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9980489 | 0.77 | NAAA (0.35) | — | |
| SCHEMBL1742070 | 0.73 | RECQL (0.38) | — | |
| SCHEMBL9057282 | 0.72 | ALDH1A1 (0.32) | — | |
| SCHEMBL28883758 | 0.66 | — | — | |
| SCHEMBL715975 | 0.64 | ALDH1A1 (0.61) | — | |
| SCHEMBL27599801 | 0.64 | NAAA (0.47) | — | |
| SCHEMBL165589 | 0.64 | NAAA (0.39) | — | |
| SCHEMBL386957 | 0.64 | NAAA (0.39) | — | |
| SCHEMBL118947 | 0.63 | ALDH1A1 (0.50) | — | |
| SCHEMBL4631695 | 0.62 | CA2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012619-B2 | Methods of use for an NADPH-regeneration system based on a monomeric isocitrate dehydrogenase | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2024-06-18 | — | — | US | claimed |
| CN-117849019-A | Preparation method and application of surface-enhanced Raman scattering immunodetection system for prostate cancer exosomes | 宁波大学 | 2024-04-09 | — | — | CN | claimed |
| US-20230143972-A1 | NADPH-REGENERATION SYSTEM BASED ON MONOMERIC ISOCITRATE DEHYDROGENASE AND USE THEREOF | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2023-05-11 | — | — | US | claimed |
| EP-4107284-A1 | IN SITU ANALYSIS OF CHROMATIN INTERACTION | 10X Genomics, Inc. (US) | 2022-12-28 | — | — | EP | claimed |
| CN-115485391-A | In situ analysis of chromatin interactions | 10X基因组学有限公司 | 2022-12-16 | — | — | CN | claimed |
| US-20220267742-A1 | NADPH-REGENERATION SYSTEM BASED ON MONOMERIC ISOCITRATE DEHYDROGENASE AND USE THEREOF | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2022-08-25 | — | — | US | claimed |
| CN-107614514-B | Antibody-specific modification using IgG-binding peptides | 国立大学法人鹿儿岛大学 | 2022-03-01 | — | — | CN | claimed |
| CN-107982547-B | Application of redox response chitosan-liposome | 大连民族大学 | 2020-10-16 | — | — | CN | claimed |
| US-20100226961-A1 | CROSS-LINKED BIOACTIVE HYDROGEL MATRICES | PIONEER SURGICAL ORTHOBIOLOGICS, INC. | 2010-09-09 | — | — | US | claimed |
| WO-2010063725-A2 | STRUCTURING PARTICLES INTO USEFUL STRUCTURES AND THEIR USE IN LIFE SCIENCE | MATTIASSON BO (SE) | 2010-06-10 | — | — | WO | claimed |
| WO-2009080308-A1 | MEANS ANDS METHODS OF PROCESSING BIOLOGICAL SAMPLES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-07-02 | — | — | WO | claimed |
| EP-2073011-A1 | Means and methods of processing biological samples | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-06-24 | — | — | EP | claimed |
| EP-1476202-B1 | CROSS-LINKED BIOACTIVE HYDROGEL MATRICES | ENCELLE INC (US) | 2009-01-14 | — | — | EP | claimed |
| EP-1476202-A1 | CROSS-LINKED BIOACTIVE HYDROGEL MATRICES | Encelle, Inc. (US) | 2004-11-17 | — | — | EP | claimed |
| US-20030232746-A1 | Cross-linked bioactive hydrogel matrices | ENCELLE, INC. | 2003-12-18 | — | — | US | claimed |
| WO-2003072155-A1 | CROSS-LINKED BIOACTIVE HYDROGEL MATRICES | ENCELLE, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-6592814-B2 | Lactoferrin microbiocidal coatings | JOHNSON & JOHNSON VISION CARE, INC. | 2003-07-15 | — | — | US | claimed |
| US-4665089-A | IMIDOESTER OR N-HYDROXYSUCCINIMIDE ESTER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1987-05-12 | — | — | US | claimed |
| EP-0199103-A2 | Process for preventing or reversing cataract formation using protein modification reagents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1986-10-29 | — | — | EP | claimed |
| CN-118326005-A | SERS sensor for DNA methylation detection and preparation method and application thereof | 福建师范大学 | 2024-07-12 | — | — | CN | disclosed |
| US-12012619-B2 | Methods of use for an NADPH-regeneration system based on a monomeric isocitrate dehydrogenase | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2024-06-18 | — | — | US | disclosed |
| CN-117849019-A | Preparation method and application of surface-enhanced Raman scattering immunodetection system for prostate cancer exosomes | 宁波大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-116570757-B | Double-component in-situ adhesive based on super-charged protein, and preparation method and application thereof | 北京镧系生物科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116710138-A | Peptide crosslinking agent and crosslinked peptide crosslinked by the same | 国立大学法人鹿儿岛大学 | 2023-09-05 | — | — | CN | disclosed |
| US-20230256019-A1 | METHOD FOR STABILIZING BINDING OF NK CELL AND ANTIBODY, AND USE THEREOF | GAIA BIOMEDICINE INC. (JP) | 2023-08-17 | — | — | US | disclosed |
| CN-116570757-A | Double-component in-situ adhesive based on super-charged protein, and preparation method and application thereof | 北京镧系生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230212311-A1 | FIXED DOSING OF HER ANTIBODIES | GENENTECH, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| CN-116391047-A | Mass spectrometry-based methods and kits for nucleic acid detection and disease diagnosis | YYZ医药科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116194776-A | Systems and methods for cell capture, biomarker detection, and contactless cell lysis | 达特茅斯学院托管会 | 2023-05-30 | — | — | CN | disclosed |
| US-20230143972-A1 | NADPH-REGENERATION SYSTEM BASED ON MONOMERIC ISOCITRATE DEHYDROGENASE AND USE THEREOF | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2023-05-11 | — | — | US | disclosed |
| EP-4173640-A1 | METHOD FOR STABILIZING BINDING OF ANTIBODY TO NK CELL AND USE THEREOF | GAIA BioMedicine Inc. (JP) | 2023-05-03 | — | — | EP | disclosed |
| EP-4107284-A1 | IN SITU ANALYSIS OF CHROMATIN INTERACTION | 10X Genomics, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| CN-115485391-A | In situ analysis of chromatin interactions | 10X基因组学有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220287949-A1 | SAFE PARTICLES FOR THE INTRODUCTION OF USEFUL CHEMICAL AGENTS IN THE BODY WITH CONTROLLED ACTIVATION | BAMBU VAULT LLC (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220267742-A1 | NADPH-REGENERATION SYSTEM BASED ON MONOMERIC ISOCITRATE DEHYDROGENASE AND USE THEREOF | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2022-08-25 | — | — | US | disclosed |
| US-20220226253-A1 | SAFE PARTICLES FOR THE INTRODUCTION OF USEFUL CHEMICAL AGENTS IN THE BODY WITH CONTROLLED ACTIVATION | BAMBU VAULT LLC (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220218878-A1 | CONTROLLED HEAT DELIVERY COMPOSITIONS | BAMBU VAULT LLC (US) | 2022-07-14 | — | — | US | disclosed |
| CN-107614514-B | Antibody-specific modification using IgG-binding peptides | 国立大学法人鹿儿岛大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-114096256-A | Methods and compositions for predicting the efficacy of a BCL-2/BCL-XL inhibitor on cancer | 苏州亚盛药业有限公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-3927754-A1 | SAFE PARTICLES FOR THE INTRODUCTION OF USEFUL CHEMICAL AGENTS IN THE BODY WITH CONTROLLED ACTIVATION | Bambu Vault LLC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20210277091-A1 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | UNIVERSITY OF MARYLAND, BALTIMORE | 2021-09-09 | — | — | US | disclosed |
| US-20210254140-A1 | SITU ANALYSIS OF CHROMATIN INTERACTION | 10X GENOMICS INC (US) | 2021-08-19 | — | — | US | disclosed |
| EP-2830653-B1 | MICROPARTICLE/NANOPARTICLE VACCINE AGAINST MALARIA | ARTIFICIAL CELL TECH INC (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3860648-A1 | ANTI-MALARIA COMPOSITIONS AND METHODS | Artificial Cell Technologies, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10941191-B2 | Immunoglobulin constant region Fc receptor binding agents | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-03-09 | — | — | US | disclosed |
| CN-112236040-A | Recombinant milk protein polymers | 完美日股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2020243047-A1 | CONTROLLED HEAT DELIVERY COMPOSITIONS | BAMBU VAULT LLC (US) | 2020-12-03 | — | — | WO | disclosed |
| US-10851154-B2 | Immunoglobulin constant region Fc receptor binding agents | GLIKNIK INC. (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2020228695-A1 | METHOD AND COMPOSITION FOR PREDICTING EFFICACY OF BCL-2/BCL-XL INHIBITORS ON CANCER | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-11-19 | — | — | WO | disclosed |
| CN-107982547-B | Application of redox response chitosan-liposome | 大连民族大学 | 2020-10-16 | — | — | CN | disclosed |
| EP-3698807-A1 | FIXED DOSING OF HER ANTIBODIES | Genentech, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200239595-A1 | FIXED DOSING OF HER ANTIBODIES | GENENTECH, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200108132-A1 | ANTI-MALARIA COMPOSITIONS AND METHODS | ARTIFICIAL CELL TECHNOLOGIES, INC. | 2020-04-09 | — | — | US | disclosed |
| WO-2020072399-A1 | ANTI-MALARIA COMPOSITIONS AND METHODS | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-3192529-B1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | FAULSTICH HEINZ DR (DE) | 2020-03-25 | — | — | EP | disclosed |
| US-10588954-B2 | Anti-malaria compositions and methods | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20200079825-A1 | RARE PHOSPHORYLATED HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES THAT ARE INVOLVED IN NEURONAL UPTAKE AND PROPAGATION AND APPLICATIONS THEREOF | The General Hostital Corporation (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190338051-A1 | PREPARATION METHOD FOR AND USE OF REDOX-RESPONSIVE CHITOSAN-LIPOSOME | DALIAN MINZU UNIVERSITY (CN) | 2019-11-07 | — | — | US | disclosed |
| US-20190218275-A1 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-07-18 | — | — | US | disclosed |
| US-10309921-B2 | Label-free electrochemical biosensor | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3485912-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20180371035-A1 | SOLUBLE HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES AND APPLICATIONS THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2018-12-27 | — | — | US | disclosed |
| EP-3409687-A1 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | University of Maryland, Baltimore (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-1846030-B1 | FIXED DOSING OF HER ANTIBODIES | GENENTECH INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180327510-A1 | FIXED DOSING OF HER ANTIBODIES | GENENTECH, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| EP-3080611-B1 | SOLUBLE HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES AND APPLICATIONS THEREOF | MASSACHUSETTS GEN HOSPITAL (US) | 2018-11-14 | — | — | EP | disclosed |
| EP-2590675-B1 | RESPIRATORY SYNCYTIAL VIRUS ANTIGENIC COMPOSITIONS AND METHODS | ARTIFICIAL CELL TECH INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180236072-A1 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS | GENENTECH, INC. (US) | 2018-08-23 | — | — | US | disclosed |
| US-20180221465-A1 | ANTI-MALARIA COMPOSITIONS AND METHODS | TARGETED NANO TECHNOLOGIES LLC | 2018-08-09 | — | — | US | disclosed |
| EP-3349788-A1 | ANTI-MALARIA COMPOSITIONS AND METHODS | Artificial Cell Technologies, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180186862-A1 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | GLIKNIK INC. | 2018-07-05 | — | — | US | disclosed |
| US-9968665-B2 | Anti-malaria compositions and methods | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| EP-2641913-B1 | Immunoglobulin constant region Fc receptor binding agents | UNIV MARYLAND (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9925252-B2 | Antigenic compositions and methods | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926362-B2 | Immunoglobulin constant region Fc receptor binding agents | GLIKNIK INC. (US) | 2018-03-27 | — | — | US | disclosed |
| EP-2614137-B1 | CELLS FOR CHROMATIN IMMUNOPRECIPITATION AND METHODS FOR MAKING | SIGMA ALDRICH CO LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017160599-A1 | USE OF CD300B ANTAGONISTS TO TREAT SEPSIS AND SEPTIC SHOCK | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20170218049-A1 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | UNIVERSITY OF MARYLAND, BALTIMORE | 2017-08-03 | — | — | US | disclosed |
| EP-3195879-A1 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS | Genentech, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3192529-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-9671393-B2 | Cells for chromatin immunoprecipitation and methods for making | SIGMA-ALDRICH CO., LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170128558-A1 | ANTI-MALARIA COMPOSITIONS AND METHODS | TARGETED NANO TECHNOLOGIES LLC | 2017-05-11 | — | — | US | disclosed |
| WO-2017053735-A1 | HUMAN RPN2 DERIVED PEPTIDES USEFUL FOR TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017048689-A1 | ANTI-MALARIA COMPOSITIONS AND METHODS | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-2416804-B1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | FAULSTICH HEINZ DR (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20170037147-A1 | FIXED DOSING OF HER ANTIBODIES | GENENTECH, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| WO-2017011556-A1 | RARE PHOSPHORYLATED HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES THAT ARE INVOLVED IN NEURONAL UPTAKE AND PROPAGATION AND APPLICATIONS THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20160355570-A1 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | GLIKNIK INC. | 2016-12-08 | — | — | US | disclosed |
| US-9512210-B2 | Immunoglobulin constant region Fc receptor binding agents | GLIKNIK INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160333063-A1 | SOLUBLE HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES AND APPLICATIONS THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2016-11-17 | — | — | US | disclosed |
| US-9487593-B2 | Respiratory syncytial virus antigenic compositions and methods | ARTIFICIAL CELL TECHNOLOGIES, INC (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2830652-B1 | ANTIGENIC COMPOSITIONS AND METHODS | ARTIFICIAL CELL TECHNOLOGIES INC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-3080611-A1 | SOLUBLE HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES AND APPLICATIONS THEREOF | The General Hospital Corporation (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2016156469-A1 | GENOME ARCHITECTURE MAPPING ON CHROMATIN | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-10-06 | — | — | WO | disclosed |
| US-20160280768-A1 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | GLIKNIK INC. | 2016-09-29 | — | — | US | disclosed |
| US-9433671-B2 | Anti-malaria compositions and methods | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160166669-A1 | ANTIGENIC COMPOSITIONS AND METHODS | TARGETED NANO TECHNOLOGIES LLC | 2016-06-16 | — | — | US | disclosed |
| US-9302001-B2 | Antigenic compositions and methods | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160089450-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-03-31 | — | — | US | disclosed |
| US-9233173-B2 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-01-12 | — | — | US | disclosed |
| EP-2185589-B1 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | UNIV MARYLAND (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150273059-A1 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS | GENENTECH, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150247816-A1 | LABEL-FREE ELECTROCHEMICAL BIOSENSOR | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2015089375-A1 | SOLUBLE HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES AND APPLICATIONS THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150093381-A1 | FIXED DOSING OF HER ANTIBODIES | GENENTECH, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150056185-A1 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | GLIKNIK INC. (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2830652-A1 | ANTIGENIC COMPOSITIONS AND METHODS | Artificial Cell Technologies, Inc. (US) | 2015-02-04 | — | — | EP | disclosed |
| EP-2830653-A1 | MICROPARTICLE VACCINE AGAINST MALARIA | Artificial Cell Technologies, Inc. (US) | 2015-02-04 | — | — | EP | disclosed |
| US-20150030682-A1 | ANTIGENIC COMPOSITIONS AND METHODS | TARGETED NANO TECHNOLOGIES LLC | 2015-01-29 | — | — | US | disclosed |
| US-20150021511-A1 | ORGANIC/INORGANIC NANOCOMPOSITE CAPABLE OF ADSORPTION/DESORPTION OF METAL IONS, AND PREPARATION METHOD THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2015-01-22 | — | — | US | disclosed |
| US-20140335075-A1 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | GLIKNIK INC (US) | 2014-11-13 | — | — | US | disclosed |
| US-8871483-B1 | Biofuel cell electrocatalysts utilizing enzyme-carbon nanotube adducts | STC.UNM (US) | 2014-10-28 | — | — | US | disclosed |
| EP-1771482-B1 | HER2 ANTIBODY COMPOSITION | GENENTECH INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20140186347-A1 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS | GENENTECH, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8691232-B2 | Extending time to disease progression or survival in cancer patients | GENENTECH, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8680237-B2 | Immunoglobulin constant region FC receptor binding agents | GLIKNIK INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1850874-B1 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN OVARIAN CANCER PATIENTS USING PERTUZUMAB | GENENTECH INC (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2013148426-A1 | MICROPARTICLE VACCINE AGAINST MALARIA | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013148427-A1 | ANTIGENIC COMPOSITIONS AND METHODS | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20130259945-A1 | ANTI-MALARIA COMPOSITIONS AND METHODS | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2641913-A2 | Immunoglobulin constant region Fc receptor binding agents | University of Maryland, Baltimore (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8535656-B2 | Amphiphilic polymer-protein conjugates and methods of use thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-09-17 | — | — | US | disclosed |
| EP-2614137-A2 | CELLS FOR CHROMATIN IMMUNOPRECIPITATION AND METHODS FOR MAKING | Sigma-Aldrich Co. LLC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20130172198-A1 | CELLS FOR CHROMATIN IMMUNOPRECIPITATION AND METHODS FOR MAKING | SIGMA-ALDRICH CO., LLC (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130142865-A1 | FIXED DOSING OF HER ANTIBODIES | GENENTECH, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| EP-2590675-A1 | RESPIRATORY SYNCYTIAL VIRUS ANTIGENIC COMPOSITIONS AND METHODS | Artificial Cell Technologies, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8404234-B2 | Fixed dosing of HER antibodies | GENENTECH, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-1755671-B1 | THERAPY OF PLATINUM-RESISTANT CANCER | GENENTECH INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2263691-B1 | Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4) | HOFFMANN LA ROCHE (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-8241630-B2 | HER2 antibody composition | GENENTECH, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120171152-A1 | Amphiphilic Polymer-Protein Conjugates and Methods of Use Thereof | SAINT LOUIS UNIVERSITY | 2012-07-05 | — | — | US | disclosed |
| US-8168222-B2 | Amphiphilic polymer-protein conjugates and methods of use thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120100161-A1 | Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2012-04-26 | — | — | US | disclosed |
| WO-2012033714-A2 | CELLS FOR CHROMATIN IMMUNOPRECIPITATION AND METHODS FOR MAKING | SIGMA-ALDRICH CO., LLC (US) | 2012-03-15 | — | — | WO | disclosed |
| EP-1585966-B8 | Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4 | HOFFMANN LA ROCHE (CH) | 2012-03-07 | — | — | EP | disclosed |
| EP-2416804-A2 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120035093-A1 | Amphiphilic Polymer-Protein Conjugates and Methods of Use Thereof | BATRAKOVA ELENA V (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120009254-A1 | Respiratory Syncytial Virus Antigenic Compositions and Methods | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2012006395-A1 | RESPIRATORY SYNCYTIAL VIRUS ANTIGENIC COMPOSITIONS AND METHODS | ARTIFICIAL CELL TECHNOLOGIES, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| EP-2399605-A1 | Extending time to disease progression or survival in cancer patients | Genentech, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-1585966-B1 | Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4 | GENENTECH INC (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110275096-A1 | Detection of Activation of Endothelial Cells as Surrogate Marker for Angiogenesis | MONOGRAM BIOSCIENCES, INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110244465-A1 | METHODS OF PREDICTING AND MONITORING TYROSINE KINASE INHIBITOR THERAPY | PROMETHEUS LABORATORIES INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8017151-B2 | Amphiphilic polymer-protein conjugates and methods of use thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA BY AND BEHALF OF THE UNIVERSITY OF NEBRASKA MEDICAL CENTER (US) | 2011-09-13 | — | — | US | disclosed |
| WO-2011084485-A1 | ISOLATION OF ACTIVELY TRANSLATED MRNAS FROM A SMALL NUMBER OF CELLS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110165157-A1 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS | GENENTECH, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110117097-A1 | HER2 ANTIBODY COMPOSITION | GENENTECH, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7939267-B2 | Detection of activation of endothelial cells as surrogate marker for angiogenesis | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2011041586-A1 | ELECTROMAGNETIC DETECTION OF ANALYTES | VIROGENOMICS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| US-7908091-B2 | Methods of predicting and monitoring tyrosine kinase inhibitor therapy | PROMETHEUS LABORATORIES INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7879325-B2 | Estrogen specific immunoglobulin for use in treatment and prevention of breast cancer | GENENTECH, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| EP-2263691-A1 | Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4) | Genentech, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010115629-A2 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100239633-A1 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | UNIVERSITY OF MARYLAND BALTIMORE (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010063725-A2 | STRUCTURING PARTICLES INTO USEFUL STRUCTURES AND THEIR USE IN LIFE SCIENCE | MATTIASSON BO (SE) | 2010-06-10 | — | — | WO | disclosed |
| EP-2185589-A2 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | University Of Maryland, Baltimore (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2008151088-A9 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100028292-A1 | Amphiphilic Polymer-Protein Conjugates and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-04 | — | — | US | disclosed |
| US-20090285837-A1 | HER2 ANTIBODY COMPOSITION | GENENTECH, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090186073-A1 | Design of Delivery Vehicle Based On Rolling Model | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2009-07-23 | — | — | US | disclosed |
| US-7560111-B2 | HER2 antibody composition | GENENTECH, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| WO-2009080308-A1 | MEANS ANDS METHODS OF PROCESSING BIOLOGICAL SAMPLES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-07-02 | — | — | WO | disclosed |
| EP-2073011-A1 | Means and methods of processing biological samples | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-20090155259-A1 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS | GENENTECH, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090081223-A1 | FIXED DOSING OF HER ANTIBODIES | GENENTECH, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090011043-A1 | TISSUE SEALANT MADE FROM WHOLE BLOOD | PROVIDENCE HEALTH SYSTEM | 2009-01-08 | — | — | US | disclosed |
| WO-2008151088-A2 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-12-11 | — | — | WO | disclosed |
| US-7449184-B2 | Fixed dosing of HER antibodies | GENENTECH, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1095665-B1 | WOUND-COVERING PREPARATION, WOUND-COVERING MATERIAL, AND METHOD OF WOUND HEALING | NOF CORP (JP) | 2008-09-03 | — | — | EP | disclosed |
| EP-1850874-A2 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS USING A HER DIMERIZATION INHIBITOR | Genentech, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070254295-A1 | METHODS OF PREDICTING AND MONITORING TYROSINE KINASE INHIBITOR THERAPY | PROMETHEUS LABORATORIES INC. (US) | 2007-11-01 | — | — | US | disclosed |
| EP-1846030-A1 | FIXED DOSING OF HER ANTIBODIES | Genentech, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007109571-A2 | METHODS OF PREDICTING AND MONITORING TYROSINE KINASE INHIBITOR THERAPY | PROMETHEUS LABORATORIES, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070092870-A1 | Detection of biomolecules | NATIONAL SCIENCE FOUNDATION | 2007-04-26 | — | — | US | disclosed |
| EP-1771482-A2 | HER2 ANTIBODY COMPOSITION | Genentech, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | disclosed |
| US-7186274-B2 | Method for treating human keratin fibers with organomodified metallic particles | L'OREAL (FR) | 2007-03-06 | — | — | US | disclosed |
| EP-1755671-A1 | THERAPY OF PLATINUM-RESISTANT CANCER | GENENTECH, INC. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1585966-A4 | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES | GENENTECH INC (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006007398-A9 | THERAPY OF PLATINUM-RESISTANT CANCER | GENENTECH INC (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2006096861-A9 | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) | GENENTECH INC (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060239946-A1 | Cosmetic composition and method for treating keratinous materials, comprising a photodimerizable compound | L'OREAL (FR) | 2006-10-26 | — | — | US | disclosed |
| WO-2006096861-A2 | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) | GENENTECH, INC. (US) | 2006-09-14 | — | — | WO | disclosed |
| US-20060204505-A1 | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) | GENENTECH, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060199231-A1 | Detection of activation of endothelial cells as surrogate marker for angiogenesis | MONOGRAM BIOSCIENCES, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006091693-A2 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS USING A HER DIMERIZATION INHIBITOR | GENENTECH, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006078307-A1 | FIXED DOSING OF HER ANTIBODIES | GENENTECH, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060165702-A1 | Fixed dosing of HER antibodies | GENENTECH, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060110379-A1 | Linkage of agents using microparticles | PERICOR SCIENCE, INC. (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2006052788-A2 | DETECTION OF ACTIVATION OF ENDOTHELIAL CELLS AS SURROGATE MARKER FOR ANGIOGENESIS | MONOGRAM BIOSCIENCES, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006033700-A2 | HER2 ANTIBODY COMPOSITION | GENENTECH, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060051317-A1 | Amphiphilic polymer-protein conjugates and methods of use thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA BY AND BEHALF OF THE UNIVERSITY OF NEBRASKA MEDICAL CENTER | 2006-03-09 | — | — | US | disclosed |
| US-20060024313-A1 | Agents that disrupt dimer formation in DPP-IV family of prolyl dipeptidases | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-02-02 | — | — | US | disclosed |
| US-20060018899-A1 | HER2 antibody composition | GENENTECH, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2006007398-A1 | THERAPY OF PLATINUM-RESISTANT CANCER | GENENTECH, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060013819-A1 | Therapy of platinum-resistant cancer | GENENTECH, INC. | 2006-01-19 | — | — | US | disclosed |
| EP-1485115-A4 | OLIGO(ETHYLENE GLYCOL)-TERMINATED 1,2-DITHIOLANES AND THEIR CONJUGATES USEFUL FOR PREPARING SELF-ASSEMBLED MONOLAYERS | NELSON DEANNA J (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6958148-B1 | Linkage of agents to body tissue using microparticles and transglutaminase | PERICOR SCIENCE, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1585966-A2 | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES | GENENTECH, INC. (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1585966-A3 | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES | GENENTECH, INC. (US) | 2005-09-01 | — | — | EP | disclosed |
| EP-1485115-A2 | OLIGO(ETHYLENE GLYCOL)-TERMINATED 1,2-DITHIOLANES AND THEIR CONJUGATES USEFUL FOR PREPARING SELF-ASSEMBLED MONOLAYERS | Nelson, Deanna J. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6821529-B2 | OLIGO(ETHYLENE GLYCOL)-TERMINATED 3-ALKYL-1,2-DITHIOLANE FOR USE AS PART OF SUPPORT IN CHEMICAL ANALYSIS | NELSON DEANNA JEAN (US) | 2004-11-23 | — | — | US | disclosed |
| US-6770179-B1 | SUCH AS ATTACHMENT OF OCTADECYL THIOL TO TITANIUM | UNIVERSITE DE MONTREAL (CA) | 2004-08-03 | — | — | US | disclosed |
| US-6756354-B2 | STABILIZATION OF DRUGS | NELSON DEANNA JEAN (US) | 2004-06-29 | — | — | US | disclosed |
| US-20040106161-A1 | Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies | F. HOFFMANN - LA ROCHE AG (CH) | 2004-06-03 | — | — | US | disclosed |
| US-6706260-B1 | COMPRISED OF POLYMER HAVING SUCH AS 2-METHACRYLOYLOXYETHYL PHOSPHORYLCHOLINE UNITS; CLEANING AND NECROTIC TISSUE REMOVAL; NONIRRITATING; ACCELERATING REEPITHELIALIZATION AND GRANULATION | NOF CORPORATION (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20040042993-A1 | Composition containing an active agent and a ligand-receptor system, and process | L'OREAL (FR) | 2004-03-04 | — | — | US | disclosed |
| WO-2004008099-A2 | METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES | GENENTECH, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20040010864-A1 | Method for treating human keratin fibers with organomodified metallic particles | L'OREAL (FR) | 2004-01-22 | — | — | US | disclosed |
| US-6627200-B1 | Utilization of CD 137 in order to promote the proliferation of peripheral monocytes | MERCKLE GMBH (DE) | 2003-09-30 | — | — | US | disclosed |
| WO-2003079403-A2 | OLIGO(ETHYLENE GLYCOL)-TERMINATED 1,2-DITHIOLANES AND THEIR CONJUGATES USEFUL FOR PREPARING SELF-ASSEMBLED MONOLAYERS | NELSON DEANNA J (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-1303260-A2 | LINKAGE OF AGENTS USING MICROPARTICLES | Pericor Science, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030059865-A1 | Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers | NELSON DEANNA JEAN (US) | 2003-03-27 | — | — | US | disclosed |
| EP-1292314-A2 | METHOD FOR TREATING RESPIRATORY DISORDERS ASSOCIATED WITH PULMONARY ELASTIC FIBER INJURY COMPRISING THE USE OF GLYCOSAMINOGLYCANS | The Trustees of Columbia University in the City of New York (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030044402-A1 | Oligo(ethylene glycol)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers | NELSON DEANNA JEAN (US) | 2003-03-06 | — | — | US | disclosed |
| US-20020086852-A1 | Method for treating respiratory disorders associated with pulmonary elastic fiber injury | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2002-07-04 | — | — | US | disclosed |
| EP-1203141-A1 | LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002007707-A2 | LINKAGE OF AGENTS USING MICROPARTICLES | PERICOR SCIENCE, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001093846-A2 | METHOD FOR TREATING RESPIRATORY DISORDERS ASSOCIATED WITH PULMONARY ELASTIC FIBER INJURY COMPRISING THE USE OF CLYCOSAMINOGLYCANS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2001-12-13 | — | — | WO | disclosed |
| EP-1095665-A1 | WOUND-COVERING PREPARATION, WOUND-COVERING MATERIAL, AND METHOD OF WOUND HEALING | NOF CORPORATION (JP) | 2001-05-02 | — | — | EP | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| US-4959309-A | Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays | MOLECULAR DIAGNOSTICS, INC. (US) | 1990-09-25 | — | — | US | disclosed |
| US-4737454-A | Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays | MOLECULAR DIAGNOSTICS, INC. (US) | 1988-04-12 | — | — | US | disclosed |
| US-4665089-A | IMIDOESTER OR N-HYDROXYSUCCINIMIDE ESTER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0131830-B1 | LABELLED NUCLEIC ACID PROBES AND ADDUCTS FOR THEIR PREPARATION | MOLECULAR DIAGNOSTICS, INC. (US) | 1986-12-10 | — | — | EP | disclosed |
| EP-0199103-A2 | Process for preventing or reversing cataract formation using protein modification reagents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1986-10-29 | — | — | EP | disclosed |
| EP-0131830-A1 | Labelled nucleic acid probes and adducts for their preparation | MOLECULAR DIAGNOSTICS, INC. (US) | 1985-01-23 | — | — | EP | disclosed |
| US-4349530-A | Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal | THE OHIO STATE UNIVERSITY (US) | 1982-09-14 | — | — | US | disclosed |
| WO-1982001994-A1 | IMPLANTS,MICROBEADS,MICROCAPSULES,AND METHOD FOR THEIR PREPARATION | UNIV OHIO (US) | 1982-06-24 | — | — | WO | disclosed |
| EP-0054396-A1 | Implants, microbeads, microcapsules, and method for their preparation | The Ohio State University (US) | 1982-06-23 | — | — | EP | disclosed |
| EP-0054396-A1 | Implants, microbeads, microcapsules, and method for their preparation | The Ohio State University (US) | 1982-06-23 | — | — | EP | disclosed |